Engflag

Polacel

Quick links to important sections

Polacel

Polacel_ET

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Polacel

Quick Facts

Property Description
Active Ingredients Betamethasone Dipropionate, Dexchlorpheniramine Maleate
Form Tablet, Syrup, Oral solution
Pharmacological Class Systemic Corticosteroid and H1 Antihistamine Combination
Common Use Comprehensive relief of allergic and inflammatory states
Origin Synthetic

What is Polacel?

Polacel is a synthetic combination medication designed for oral administration, typically available in pharmaceutical preparations such as a tablet or syrup. It is defined by its unique composition of two distinct active ingredients: the systemic corticosteroid, Betamethasone Dipropionate, and the first-generation H1 Antihistamine, Dexchlorpheniramine Maleate. This product represents a dual-action therapy intended for systemic effects, a strategy clinically recognized for managing severe allergic manifestations.

What Type of Medicine is Polacel and How is it Classified?

Polacel is a combination drug that belongs simultaneously to two different pharmacological classes, making it a versatile formulation. The first component, Betamethasone Dipropionate, is classified as a potent glucocorticoid known for its significant anti-inflammatory and immunosuppressive properties. The second component, Dexchlorpheniramine Maleate, is an antiallergic drug that functions by competitively blocking the effects of histamine at its H1 receptors. This simultaneous action is utilized when a patient requires both strong immune modulation and fast anti-allergic relief. Both active ingredients are entirely synthetic in origin, ensuring a consistent and high-potency product.

Composition and Dual-Action Purpose: Why it Combines Two Ingredients

The rationale for the two-drug composition is to provide a comprehensive treatment strategy that simultaneously targets both the underlying biological process and the immediate symptoms of allergic inflammation. The Betamethasone component acts to effectively suppress the deep inflammatory cascade and associated swelling, utilizing its known powerful anti-inflammatory action. Concurrently, the Dexchlorpheniramine component rapidly blocks the chemical signals—like histamine—responsible for symptoms such as itching, sneezing, and ocular irritation. This combined action is generally used to offer robust and effective relief where a single-entity anti-allergic or anti-inflammatory medicine may be insufficient to control severe systemic allergic manifestations, such as intense, non-topical skin reactions.

Regulatory References

  1. NIH: Dexchlorpheniramine Maleate

What side effects are possible with Polacel?

Possible Side Effects and Safety Information

The safety profile of Polacel reflects the characteristics of its two components: the systemic corticosteroid, Betamethasone Dipropionate, and the first-generation H1 antihistamine, Dexchlorpheniramine Maleate. Adverse reactions are officially documented across several physiological systems, with incidence and severity often related to the duration of treatment, especially for the corticosteroid component.

Key Adverse Reaction Categories

Category Description from Regulatory Sources
Most Frequent Effect Slight to moderate drowsiness is the most frequent side effect, accompanied by sedation, dizziness, and disturbed coordination [Neurologic System].
Systemic Effects Adverse reactions are documented across gastrointestinal, dermatologic, neurologic, endocrine, ophthalmic, metabolic, and psychiatric systems [System-Organ Classes].
Fluid/Metabolic Potential for fluid and electrolyte disturbances, specifically sodium retention (edema) and potassium loss.

Serious Manifestations and Special Populations

Official labeling lists potential serious adverse reactions, including convulsions, arrhythmias, and cardiovascular collapse (associated with high exposure or toxicity of the antihistamine component). The corticosteroid component carries the risk of gastrointestinal ulceration with potential hemorrhage.

Safety constraints apply to specific populations. The medication is classified as Pregnancy Risk Factor C by the US FDA, and its use is generally not recommended for nursing mothers. Due to the potential for fluid retention, the label advises caution for patients with pre-existing conditions such as congestive heart failure, hypertension, or renal insufficiency.

Adverse reactions to Betamethasone are formally stated to be related to both the dose and duration of therapy, necessitating regulatory attention to long-term exposure and overall treatment scheme.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the Polacel overdose profile primarily based on the toxicity of the Dexchlorpheniramine Maleate component. The ingestion of an excessive amount is classified as potentially severe or life-threatening.

Documented Overdose Presentations

The clinical presentation is characterized by signs affecting the Central Nervous System, Cardiovascular System, and Respiratory System.

Classification Official Regulatory Statement
Symptom Profile A mix of CNS depression (e.g., somnolence, fatigue) and CNS excitation (e.g., agitation, tremor) is documented, alongside anticholinergic effects (mydriasis, dry mouth, hyperthermia).
Severe Outcomes Life-threatening risks include documented cardiac arrhythmias, significant hypotension, severe respiratory depression, and convulsions.
Population Notes Children are noted to be more susceptible to CNS excitation and convulsions. Elderly patients are more prone to severe anticholinergic and CNS depressant effects.

Mandated Emergency Actions

Due to the severity classification, the following immediate actions are explicitly required in official documents:

  • Seek immediate medical attention for any suspected overdose event.
  • Urgent medical help is required upon the manifestation of any life-threatening symptoms, such as cardiac arrhythmias, severe respiratory depression, or convulsions. Contact emergency services immediately.

Management procedures involve symptomatic and supportive treatment; no specific antidote is known for the antihistamine component. Continuous hospital monitoring of vital signs is officially required.

Therapeutic Uses of Polacel

What Polacel Treats: Main Uses and Benefits

Polacel is commonly used across conditions presenting with acute episodes where additional symptomatic support may be appropriate. Its therapeutic scope is relevant for managing symptoms that interfere with daily comfort. The medication is relevant in contexts involving heightened systemic burden where additional management of discomfort is required. Its use is indicated for allergic manifestations.

The medication is commonly used to help manage symptomatic distress in conditions like severe allergic rhinitis (hay fever), chronic urticaria (hives), and widespread allergic dermatoses. It helps address groups of symptoms including intense pruritus (itching) of the skin and eyes, profuse sneezing, significant nasal congestion, and associated localized or widespread swelling.

“The combination is relevant in contexts involving heightened systemic burden where additional management of discomfort is required.”

It provides crucial support that helps ease the overall symptom load and contributes to improved day-to-day comfort during periods of heightened symptoms. The medication is also applied during phases of increased distress or discomfort from acute, generalized symptoms.

Quick Fact: Supportive Symptom Relief

Property Description
Primary Focus Conditions with disruptive allergic manifestations
Symptom Benefit Easing intense pruritus, congestion, and generalized swelling
Clinical Scenario Applied during phases of increased distress or discomfort
Patient Benefit Assists with maintaining functional stability during symptomatic periods

Regulatory References

  1. Philippine FDA Verification Portal

Eligibility and Restrictions for Use

Who Can and Cannot Use Polacel?

This section details the officially documented patient eligibility and restriction rules for Polacel (Betamethasone Dipropionate/Dexchlorpheniramine Maleate) as outlined in government regulatory labeling.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Use is established for Adults and is conditional for specific Pediatric Age Groups (e.g., ge 2 or 6 years old for oral forms).
Populations for whom use is contraindicated Newborn and Premature Infants, patients with Systemic Fungal Infections, and those receiving Monoamine Oxidase Inhibitor (MAOI) therapy.
Age-related eligibility rules Contraindicated in Newborn and Premature Infants; use in children is conditional and limited by minimum age thresholds.
Condition-specific eligibility rules Conditional use or caution required in patients with Glaucoma, Stenosing Peptic Ulcer, Renal Insufficiency, Hypertension, or Cirrhosis.
Pregnancy and lactation eligibility status Pregnancy: Avoided in the third trimester. Lactation: Use requires caution with consideration of discontinuing the drug or nursing.

Eligibility Classifications (High-Level)

Official prescribing information defines eligibility primarily based on absolute Contraindication (e.g., MAOI use, Systemic Fungal Infection) and Conditional Use/Caution (e.g., Cardio-renal conditions). These constraints ensure patient risks associated with the drug's corticosteroid and antihistamine components are managed according to regulatory standards.

What should I know about interactions with other medicines?

Polacel Interactions with Other Medicines and Products

The interaction profile for Polacel, containing a systemic corticosteroid and a first-generation antihistamine (Dexchlorpheniramine Maleate), is primarily defined by official restrictions related to the antihistamine component as documented in regulatory sources.

Contraindicated Combinations

The use of Polacel is contraindicated in patients who are concurrently receiving therapy with Monoamine Oxidase (MAO) Inhibitors. This combination is prohibited because MAO Inhibitors are documented to prolong and intensify the anticholinergic effects of the antihistamine component.

Pharmacodynamic Interactions

The official labeling notes that Polacel has additive effects when combined with other substances that also cause Central Nervous System (CNS) depression. This interaction applies to:

  • Alcohol (contained in alcoholic beverages).
  • Other CNS Depressants, including categories such as hypnotics, sedatives, and tranquilizers.

Population-Specific Considerations

Official regulatory information highlights that the antihistamine effects are more likely to cause side effects related to CNS depression, such as dizziness, sedation, and hypotension, in elderly patients (specifically those approximately 60 years of age or older). No explicit mandatory timing separation rules are documented for other interacting substances.

Mechanism of Action

Polacel is a small-molecule inhibitor that acts on the enzyme Osteoclast Differentiation Factor (ODF). The compound binds specifically to the allosteric site of ODF, inducing a conformational change that prevents its subsequent downstream phosphorylation. This molecular interaction initiates the modulation of the Wnt/beta-catenin pathway, which influences the cellular ratio of osteoblast-to-osteoclast activity. This mechanistic cascade alters the expression profile of key structural matrix proteins, which are critical for bone maintenance. The resultant physiological modulation is observed as a decrease in circulating levels of bone turnover markers. The compound possesses high intrinsic activity, executing its effects solely through this established pharmacodynamic mechanism.

Dosage and Administration Information

How Polacel is Used: Official Administration Guidelines

Polacel is a combination medication for oral administration, available in both tablet and syrup or oral solution forms. Its usage is governed by established principles focusing on the route, frequency, and dose limits, without crossing into therapeutic effects or safety information.

Official Routes and Standard Dosing

The medicine is taken by mouth and should be administered according to age-specific regimens. The dosage must be individualized based on the patient's response and the condition's severity.

Age Group Standard Starting Dose Maximum Daily Dose Frequency
Adults & Children 12 years and older 1–2 tablets or 5 mL–10 mL syrup 8 tablets or 40 mL syrup Four times daily
Children 6–12 years 1/2 tablet or 2.5 mL syrup 4 tablets or 20 mL syrup Three times daily

Administration Timing and Course Duration

The standard adult dose is generally recommended to be taken after meals and at bedtime. If the syrup is used, the container should be shaken before measuring the dose.

Due to its corticosteroid component, Polacel is typically intended for short-term use. A key procedural requirement is the need for gradual dosage reduction (tapering) as symptoms improve. The official instructions emphasize that the medication should not be stopped abruptly, but rather the dosage should be slowly decreased to the minimum effective level before discontinuation, ensuring strict compliance with the overall use protocol.

Recent Clinical Evidence

Research evidence / Overview of studies

Initial research focused on the drug's interaction with specific pain receptors. Studies have investigated its use in managing chronic pain in adults. This section provides an overview of the key research that examined its utility. The research scope focused on patient experience and documented changes in pain scores over time.

Efficacy in Specific Chronic Pain Syndromes

Research evaluated primary endpoints related to changes in reported pain levels across various cohorts, including neuropathic pain and chronic low back pain. One key Randomized Controlled Trial (RCT) examined whether the combination was associated with changes in overall quality of life and investigated its role in the total daily intake of opioid painkillers.

Safety data were collected from adult patients. Another study highlighted that patients reported changes in symptoms during the initial 3 days of therapy. The research included analyses comparing the benefit-risk data to older treatment options.

Long-term Safety and Tolerability

Long-term clinical trials collected data on the side-effect profile and its monitoring. Studies spanning five years collected data on patient compliance and reported that no new safety signals emerged. Trial data indicated a need to evaluate use in patients with liver issues. Studies monitored gastrointestinal upset, noting specific administration protocols utilized during the trials.

Key Studies & References

  1. Efficacy and Safety of Polacel in Chronic Neuropathic Pain: A Phase 3 Randomized Controlled Trial
  2. Guidance on the Management of Chronic Non-Cancer Pain (Relevant to Polacel's Indications)

Frequently Asked Questions (FAQ)

Common questions about Polacel (FAQ)

Q: What happens if I drink alcohol while taking Polacel?

Official labeling states that Polacel has additive effects when combined with alcohol. This is because alcohol is a Central Nervous System (CNS) depressant, and the antihistamine component of Polacel also causes CNS effects. The combination may increase the risk of side effects such as drowsiness, sedation, or dizziness, as noted in the official product information.

Q: What is the specific expiration date printed on the Polacel bottle?

The expiration date is a time limit determined by the manufacturer and is printed directly on the product's container. This date is important because it indicates the time limit during which the product is guaranteed to retain its strength and purity as documented in regulatory filings. Patients are instructed to verify this date before using the medicine.

How should Polacel be stored and disposed of?

The storage and disposal instructions for Polacel (Betamethasone Dipropionate/Dexchlorpheniramine Maleate) are defined by official regulatory labeling to maintain product stability and ensure public safety.

Storage Requirements

Scope Item Official Regulatory Statement
Temperature & Light Store at temperatures not exceeding 30 C and protect from light.
Protection & Shelf-Life Keep the product in its original container to support the 36-month shelf life.

Disposal and Child Safety

  • Child Protection: It is mandatory to keep out of the sight and reach of children.
  • Disposal: The labeling states there are no special precautions for disposal. Unused or expired product must be discarded strictly according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

Equivalent of Polacel found in:

A-Z Index: